Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women

Summary

Prospective, open, single-arm trial of dolutegravir-tenofovir and emtricitabine or lamivudine (DTG-TDF-FTC or 3TC) in antiretroviral (ART) naïve HIV transgender women (TGW). The primary objective of this pilot study is to determine the retention in care of TGW treated with DTG-TDF-FTC or 3TC Secondary objectives: * To evaluate the efficacy of the antiretroviral regimen at week 48 ; * To describe the safety and tolerability of this regimen; * To evaluate adherence across 48 weeks; * To determine the patient satisfaction with this regimen; * To identify individual, social and contextual factors associated with adherence and retention.

Timeline

Start

2015-12

Primary completion

2019-06-28

Completion

2019-06-28

Drugs

Indications